# Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant

> **NCT01122784** · PHASE2 · COMPLETED · sponsor: **DynPort Vaccine Company LLC, A GDIT Company** · enrollment: 402 (actual)

## Conditions studied

- Plague Vaccine

## Interventions

- **BIOLOGICAL:** rF1V vaccine (with Adjuvant)
- **BIOLOGICAL:** rF1V vaccine (without Adjuvant)
- **BIOLOGICAL:** rF1V vaccine (with Adjuvant)
- **BIOLOGICAL:** rF1V vaccine (without Adjuvant)

## Key facts

- **NCT ID:** NCT01122784
- **Lead sponsor:** DynPort Vaccine Company LLC, A GDIT Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2012-05
- **Final completion:** 2012-07
- **Target enrollment:** 402 (ACTUAL)
- **Last updated:** 2020-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01122784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01122784, "Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT01122784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*